Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0079731 (
B-cell lymphoma
)
16,671
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mixed linage leukemia gene 2 (MLL2) is identified as a novel mutation gene in diffuse large
B cell lymphoma
(DLBCL). However, the significance of
MLL2 protein
expression for the prognosis of DLBCL is unclear. In this study, we detected
MLL2 protein
expression in primary gastrointestinal diffuse large
B cell lymphoma
(PGI-DLBCL) samples by using tissue microarray immunohistochemistry, and analyzed the correlation between
MLL2 protein
expression and tumor proliferation activity. In addition, we investigated clinical significance of
MLL2 protein
expression for PGI-DLBCL prognosis. We found that there was significant difference in
MLL2 protein
expression between PGI-DLBCL and reactive hyperplasia of lymph node. High expression of
MLL2 protein
indicated higher clinical stage. In older patients (>60 years) with PGI-DLBCL,
MLL2 protein
expression was positively correlated with Ki-67 expression and negatively correlated with patient survival. Our data suggest that
MLL2 protein
is overexpressed in PGI-DLBCL and appears as a prognostic factor for patients of PGI-DLBCL, especially for those older than 60 years old.
...
PMID:MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma. 2672 99